Beyond Air Announces Publication Of New Preclinical Data For The Treatment Of Autism Spectrum
Portfolio Pulse from Benzinga Newsdesk
Beyond Air, Inc. (NASDAQ:XAIR) has announced the publication of new preclinical data supporting the development of selective neuronal nitric oxide synthase (nNOS) inhibitors for the treatment of Autism Spectrum Disorder (ASD). The data, published by the Hebrew University of Jerusalem (HUJI), demonstrates a therapeutic effect for at least 10 days after a single subcutaneous injection of an extended-release nNOS inhibitor. The research observed improved cognitive memory, social interaction, and reduced anxiety-like behavior in Shank3 mutant mice.
September 18, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The new preclinical data published by Beyond Air could potentially boost the company's reputation in the medical and biopharmaceutical industry. The development of nNOS inhibitors for the treatment of ASD could open new revenue streams for the company if the product reaches the market.
The publication of new preclinical data is a positive development for Beyond Air as it demonstrates progress in their research and development efforts. If the nNOS inhibitors prove to be effective in treating ASD, it could lead to increased investor interest and potentially higher stock prices in the short term. However, it's important to note that the product is still in the preclinical stage and there are many hurdles to overcome before it can reach the market.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100